These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 23991629

  • 1. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
    Huang Z, Wan X, Liu J, Deng W, Chen A, Liu L, Liu J, Wei G, Li H, Fang D, Li Y.
    Diabetes Technol Ther; 2013 Oct; 15(10):859-69. PubMed ID: 23991629
    [Abstract] [Full Text] [Related]

  • 2. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [Abstract] [Full Text] [Related]

  • 3. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V, Rosenstock J, Patwardhan R, Salzman A.
    JAMA; 2000 Apr 05; 283(13):1695-702. PubMed ID: 10755495
    [Abstract] [Full Text] [Related]

  • 4. Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study.
    Ke W, Liu L, Liu J, Chen A, Deng W, Zhang P, Cao X, Liao Z, Xiao H, Liu J, Li Y.
    J Diabetes Res; 2016 Apr 05; 2016():6839735. PubMed ID: 26640805
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Intensive insulin therapy combined with metformin is associated with reduction in both glucose variability and nocturnal hypoglycaemia in patients with type 2 diabetes.
    Zhang Y, Zhao Z, Wang S, Zhu W, Jiang Y, Sun S, Chen C, Wang K, Mu L, Cao J, Zhou Y, Gu W, Hong J, Wang W, Ning G.
    Diabetes Metab Res Rev; 2017 Oct 05; 33(7):. PubMed ID: 28609547
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.
    Yilmaz H, Gursoy A, Sahin M, Guvener Demirag N.
    Acta Diabetol; 2007 Dec 05; 44(4):187-92. PubMed ID: 17726570
    [Abstract] [Full Text] [Related]

  • 12. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.
    Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW.
    Clin Ther; 2005 Oct 05; 27(10):1548-61. PubMed ID: 16330291
    [Abstract] [Full Text] [Related]

  • 13. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
    Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.
    Pharmacotherapy; 2005 May 05; 25(5):637-45. PubMed ID: 15899724
    [Abstract] [Full Text] [Related]

  • 14. A clinical trial to maintain glycemic control in youth with type 2 diabetes.
    TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F.
    N Engl J Med; 2012 Jun 14; 366(24):2247-56. PubMed ID: 22540912
    [Abstract] [Full Text] [Related]

  • 15. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL, Stewart J, Issa M, Lake B, Melis R.
    Clin Ther; 2005 Oct 14; 27(10):1535-47. PubMed ID: 16330290
    [Abstract] [Full Text] [Related]

  • 16. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
    Lin S, Chen M, Chen W, Lin K, Mu P, Zhu B, Xu W, Wang M, Weng J, Zeng L.
    J Diabetes Res; 2018 Oct 14; 2018():2791584. PubMed ID: 30420969
    [Abstract] [Full Text] [Related]

  • 17. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J.
    J Diabetes; 2017 Oct 14; 9(10):890-893. PubMed ID: 28661564
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.
    Osei K, Gaillard T, Schuster D.
    Metabolism; 2007 Jan 14; 56(1):24-9. PubMed ID: 17161222
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.